Karen Edelblum, PhD

About Me

Dr. Edelblum began her training in the Department of Cell & Developmental Biology at Vanderbilt University. During her graduate training, Dr. Edelblum focused on the role of Raf-1 kinase in intestinal epithelial cell survival downstream of pro-inflammatory cytokine signaling and in response to acute colitis. Fascinated by the synergy between immunological, epithelial and microbial factors during the pathogenesis of colitis, she continued her training at The University of Chicago where she developed novel advanced live imaging approaches to visualize immune/epithelial interactions in the intestinal mucosa during exposure to enteric pathogens. Combining traditional cell biology and mucosal immunology techniques has allowed Dr. Edelblum to investigate gamma delta T cell migration and how direct contact between gamma delta T cells and enterocytes confer protection against enteric pathogen invasion. Dr. Edelblum's long-term research interests are to identify how gamma delta T cell/epithelial interactions shape innate immune responses to pathogenic and commensal bacteria as a means to treat inflammatory bowel disease.

Language

English

Position

ASSOCIATE PROFESSOR | Pathology, Molecular and Cell Based Medicine

Research Topics

Autoimmunity, Cell Motility, Cellular Immunity, Gastroenterology, Imaging, Immunology, Inflammatory Bowel Disease (IBD), Integrins, Metabolism, Signal Transduction, T Cells

Multi-Disciplinary Training Areas

Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]

Education

BS, Emory University

PhD, Vanderbilt University

, The University of Chicago

Awards

2020

American Physiological Society, GI & Liver Section New Investigator Award

2016

Feldstein Medical Foundation Award

2015

Rutgers Biomedical and Health Sciences Chancellor Scholar

Research

Our research functions at the intersection between mucosal immunology, cell biology and microbiology to better understand the underlying cause of IBD. By visualizing cellular interactions in real time, we aim to provide new insight into the complexities of intestinal immunity. Through our studies, we hope to develop novel strategies to enhance barrier function in IBD patients to prevent disease relapse. Our primary interest is deciphering the role and regulation of intraepithelial lymphocytes expressing the unconventional gamma delta T cell receptor (gd IELs), which exhibit a largely protective function in the intestinal mucosa. Ongoing NIH-funded studies include investigation of (1) the role of type I interferon and the intestinal microbiota in the regulation of gd IEL function, (2) how CD103 ligation by epithelial E-cadherin contributes to the activation of downstream signaling pathways and effector function in gd IELs, and (3) the role of gd IELs in the onset of ileal Crohn's disease. We leverage unique mouse models, IEL/enteroid co-cultures, multi-omics approaches, intravital microscopy and access to IBD patient specimens to address these questions. http://www.edelblumlab.com

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Edelblum has not yet completed reporting of Industry relationships.

Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.